Antibody drug conjugates (ADCs) are the emerging class of anti-cancer therapeutic drugs. ADCs combine an antibody capable of recognizing cancer cells and cytotoxic small-molecule drugs via cleavable or non-cleavable linkers, thereby transforming the 3-unit combination into a targeted therapeutic drug for cancer treatment. In recent years, ADCs have rapidly developed and there are not only more than 14 approved drugs on the market but also many investigational drugs undergoing clinical trials. Furthermore, ADCs have shown potential for treating various diseases beyond cancer, such as Autoimmune disorders, Infectious diseases, Inflammatory conditions and so on.